A targeted therapy for melanoma by graphene oxide composite with microRNA carrier

Drug Des Devel Ther. 2018 Sep 21:12:3095-3106. doi: 10.2147/DDDT.S160088. eCollection 2018.

Abstract

Background: Nowadays, the combination of microRNA (miR) is attracting increased attention in clinical cancer trials. However, the clinical use of miR is highly limited because of certain properties such as instability, low-specificity distribution, and metabolic toxicity.

Methods: In order to improve the anti-tumor efficacy and reduce the side effects of miR in treating melanoma, a combination of graphene oxide (GO), chitosan (CS), and a cellular penetrating peptide, MPG, was prepared with solid dispersion method in this research. The research has analyzed the specific components of nano drug-loading complexes GO-CS and GO-CS-MPG through characterization research and confirmed the bio-safety of the carrier material GO-CS-MPG.

Results: The GO-CS-MPG-miR33a/miR199a nano drug-loading complex was successfully constructed and its medical effectiveness was verified. Through the subcutaneous tumor implantation experiment, an evident effect of the drug-loading complex in inhibiting melanoma cells was proven.

Conclusion: Results suggest that GO-CS-MPG may have potential applications in melanoma therapy.

Keywords: cellular penetrating peptide; chitosan; graphene oxide; melanoma; microRNA.

MeSH terms

  • Anticholesteremic Agents / chemistry
  • Anticholesteremic Agents / pharmacology*
  • Cell Proliferation / drug effects
  • Chitosan / chemistry
  • Chitosan / pharmacology*
  • DNA-Binding Proteins / chemistry
  • Drug Carriers / chemistry
  • Drug Screening Assays, Antitumor
  • Graphite / chemistry*
  • Humans
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • MicroRNAs / chemistry*
  • Oxides / chemistry*
  • Structure-Activity Relationship
  • Tumor Cells, Cultured

Substances

  • Anticholesteremic Agents
  • DNA-Binding Proteins
  • Drug Carriers
  • MPG peptide
  • MicroRNAs
  • Oxides
  • Graphite
  • Chitosan